



To: Head Dept of Rheumatology Drug
and Therapeutics Committees
cc: Consultant rheumatologists

Invitation to a streamed lecture on Juvenile idiopathic arthritis – subtypes, epidemiology, prognosis, and treatment

Juvenile idiopathic arthritis (JIA) is an umbrella term entailing a heterogeneous group of inflammatory arthritides of unknown etiology, all defined by the presence of at least one inflamed joint persisting ≥ 6 weeks, beginning before 16 years of age and that cannot be explained by other causes such as infection or trauma.

Various sets of classification criteria have been used over the years, defining the different subtypes, the prevalence and incidence of which differ, as well as does the prognosis and treatment. Finally, the treatment options for JIA have increased over the years and therefore also the possibilities of achieving remission and improving outcome.

Novartis is happy to invite you to a streamed lecture on juvenile idiopathic arthritis – subtypes, epidemiology, prognosis, and treatment, with Doctor Elisabet Berthold, Consultant Rheumatology at the Department of Rheumatology at Skåne University Hospital in Lund, who is involved in research in juvenile idiopathic arthritis.

Lecturer: Dr Elisabet Berthold, Skåne University Hospital Lund, Sweden
Time: October 6th 2022 at 12:00-13:00 CET
Venue: Webstreaming

Agenda:

12:00-12:05	Welcome	Signe Harring, Nordic Medical TA Lead Rheumatology
12:05-12:45	Juvenile Idiopathic Arthritis	Elisabet Berthold, Skåne University Hospital Lund
12:45-13:00	Questions and answers	Elisabet Berthold, Skåne University Hospital Lund

- For registration go to: www.medhub.se/IL17academy20221006 or QR code below by latest September 30th, 2022.
- Participation in the meeting requires approval from the head of department.
- Participation in the meeting is free of costs.



Welcome!
Signe Harring
Nordic Medical TA Lead Rheumatology
Novartis Healthcare A/S, Denmark